TRT Clinics Are Selling You Hormonal Chaos

Your liver makes IGF-1. That is not a side note. That is the entire point of this conversation.

When your pituitary gland releases growth hormone, that growth hormone travels to your liver, and your liver responds by producing something called IGF-1, which stands for insulin-like growth factor 1 and is essentially the downstream messenger that actually carries out most of what people attribute to growth hormone itself. Muscle protein synthesis, tissue repair, body composition changes, the things people are chasing when they talk about growth hormone or peptides, those are largely IGF-1 doing the work, not growth hormone directly.

So when you want more IGF-1, the question is not how do you inject more of it. The question is how do you support the liver's ability to produce it.

And that is exactly where estrogen enters the picture.

Estrogen, specifically estradiol, is one of the primary regulators of hepatic IGF-1 production, which means it is one of the signals that tells your liver how much IGF-1 to make. The liver has estrogen receptors. When estradiol binds to those receptors, it upregulates the machinery responsible for IGF-1 synthesis. When estradiol is suppressed, that signal goes quiet, and IGF-1 output drops with it.

This is not a minor effect. Studies in men using aromatase inhibitors, which are drugs that block the conversion of testosterone into estrogen, show meaningful reductions in circulating IGF-1 levels when estrogen is suppressed even while testosterone remains high or even elevated. The testosterone is there. The liver just is not getting the estrogen signal it needs to respond.

Now you can see where this becomes a problem.

A man goes to a TRT clinic. His testosterone is low, so they put him on testosterone therapy, which is appropriate. His body begins converting some of that testosterone into estradiol through a process called aromatization, which is the normal biological pathway that exists in men for exactly this reason. His estradiol rises, which is also expected and largely beneficial, because estradiol in men supports bone density, cardiovascular health, cognitive function, libido, and yes, IGF-1 production.

But the clinic sees the estradiol number on a lab report and treats it like a problem to be solved.

So they prescribe anastrozole, which is an aromatase inhibitor, and it does exactly what it is designed to do. It suppresses aromatization, which drives estradiol down, which removes the liver's primary signal for IGF-1 synthesis, which causes IGF-1 to drop.

Now the patient has low IGF-1. And the clinic has a solution for that too.

They sell him injectable IGF-1.

What you are looking at there is not a treatment plan. It is a manufactured deficiency being sold back to the patient as a separate problem requiring a separate product at a separate cost. The anastrozole created the IGF-1 problem. The IGF-1 injection is the clinic's answer to the problem the clinic created. And the patient is paying for all three steps of that cycle.

This matters beyond just the financial waste, because injecting exogenous IGF-1 does not replicate what your liver produces endogenously in terms of regulation. Your liver's IGF-1 output is modulated by multiple signals simultaneously including growth hormone pulses, insulin status, nutritional state, and estrogen, and that output is tuned and adjusted in real time. When you inject IGF-1 directly, you bypass all of that regulatory context, which means you are introducing a potent anabolic signal without the biological checks that normally govern it.

IGF-1 receptors are expressed in essentially every tissue in the body. Unregulated IGF-1 signaling is one of the more studied factors in cancer biology because of how it drives cellular proliferation. This is not a reason to panic about physiological IGF-1, which is the kind your own liver produces within a normal feedback system. It is a reason to be skeptical about bypassing that system with injections calibrated by a sales-driven clinic rather than your own physiology.

The legitimate medical use of IGF-1 injection is genuinely rare. It exists for a condition called growth hormone insensitivity, sometimes called Laron syndrome, where the pituitary produces growth hormone normally but the body cannot respond to it, so the liver never gets the signal to make IGF-1 in the first place. That condition affects roughly one in a million people. The use case is narrow enough that most endocrinologists will go their entire career seeing it once or not at all.

TRT clinics are not prescribing IGF-1 to that population.

The practical implication here is simpler than the biochemistry makes it sound. If a man's IGF-1 is low while he is on testosterone therapy, the first question is not what to inject. The first question is whether his estradiol has been suppressed, and if so, why, and whether that suppression was medically warranted or just reflexive over-treatment of a number that looked high on a reference range designed for a different context.

Most of the time, managing testosterone without aggressive aromatase inhibition, keeping estradiol in a physiologically appropriate range rather than driving it to the floor, will support liver IGF-1 production without any additional intervention. The system is designed to work that way. Estrogen in men is not a side effect to be eliminated. It is part of the axis.

The real problem with the TRT clinic model is not that testosterone therapy is wrong. Used appropriately, with proper monitoring and without aggressive suppression of the downstream hormones that testosterone naturally produces, it can genuinely help men who need it. The problem is the layered prescription model, where every consequence of a previous intervention becomes the justification for the next product, and the patient is kept moving through that loop indefinitely.

You cannot optimize a hormonal system by breaking one part of it and then selling the output of that broken part separately. The axis is a connected chain, and treating each link in isolation while ignoring the chain is not medicine. It is product placement dressed as protocol.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness